Story

Dermapharm Reports 2.9% Revenue Growth in First Half, Reaffirms 2026 Guidance

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20261 min read
Dermapharm Reports 2.9% Revenue Growth in First Half, Reaffirms 2026 Guidance
Text size
Background

Dermapharm Holding SE announced preliminary first-half 2026 revenue of €591 million, a 2.9% increase from the prior-year period, driven by growth in its core branded pharmaceuticals business. The German drugmaker reaffirmed its full-year financial guidance, signaling confidence in its performance for the remainder of the year.

First-Half Financials

According to the company's preliminary report, adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) for the six-month period reached €163.20 million. Total EBITDA was reported at €184.50 million.

Key performance indicators for the first half of 2026 include:

  • Revenue: €591 million
  • Adjusted EBITDA: €163.20 million
  • Adjusted EBITDA Margin: 31.20%

Segment Performance Breakdown

Sample IUX Markets – In-articleAd

The primary growth driver was the Branded Pharmaceuticals segment, which benefited from both organic expansion and the initial contributions from the acquisitions of Mucos Group and F. Trenka. This performance offset weaker results in other divisions.

Conversely, the Other Healthcare Products segment experienced a moderate revenue decline, which Dermapharm attributed to weaker consumer purchasing power. The company noted that earnings in this division were supported by favorable exchange rates and lower material costs. The Parallel Imports segment saw an expected drop in revenue following a strategic portfolio realignment, though its profitability improved due to a focus on higher-margin products.

Full-Year Outlook Confirmed

Dermapharm maintained its full-year 2026 forecast, projecting revenue between €1,182 million and €1,218 million. The company's outlook for adjusted EBITDA also remains unchanged, targeted in a range of €331 million to €341 million. Management stated that it anticipates positive trends across all segments in the second half of 2026.

Read next

More on Stocks
Back to latest news

LATEST